Vienna Insurance Group’s Neurocrine Biosciences NBIX Stock Holding History

Vienna Insurance Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.12M	Hold	30,400	–	–	1.35%	18
2026 Q1	$4M	Hold	30,400	–	–	1.53%	22
2025 Q4	$4.31M	Hold	30,400	–	–	2.1%	18
2025 Q3	$4.27M	Hold	30,400	–	–	2.52%	15
2025 Q2	$3.82M	Hold	30,400	–	–	2.4%	12
2025 Q1	$3.36M	Hold	30,400	–	–	1.83%	14
2024 Q4	$4.15M	Hold	30,400	–	–	2.42%	11
2024 Q3	$3.5M	Hold	30,400	–	–	1.49%	21
2024 Q2	$4.19M	Hold	30,400	–	–	1.64%	17
2024 Q1	$4.19M	Hold	30,400	–	–	1.64%	19
2023 Q4	$4.01M	Hold	30,400	–	–	1.84%	19
2023 Q3	$3.42M	Hold	30,400	–	–	1.52%	17
2023 Q2	$2.87M	Hold	30,400	–	–	1.33%	19
2023 Q1	$3.08M	Sell	30,400 -15,000	-33%	-$1.56M	1.81%	18
2022 Q4	$5.42M	Hold	45,400	–	–	4.2%	11
2022 Q3	$4.82M	Hold	45,400	–	–	3.4%	8
2022 Q2	$4.43M	Hold	45,400	–	–	3%	13
2022 Q1	$4.26M	Hold	45,400	–	–	2.39%	15
2021 Q4	$3.87M	Hold	45,400	–	–	2.64%	19
2021 Q3	$4.35M	Hold	45,400	–	–	2.32%	15
2021 Q2	$4.42M	Buy	45,400 +14,400	+46%	+$1.38M	2.77%	14
2021 Q1	$3.01M	Buy	+31,000	New	+$3.25M	2.88%	14

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vienna Insurance Group's NBIX Position: Q2 2026 in Review

Vienna Insurance Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 30,400 shares worth $5.12M. The position accounts for 1.35% of the portfolio, ranked #18.

Vienna Insurance Group first reported a position in NBIX in Q1 2021 and has held it in 22 quarters since. The position peaked at $5.42M in Q4 2022. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Vienna Insurance Group held 30,400 shares of Neurocrine Biosciences worth $5.12M as of Q2 2026.
Vienna Insurance Group left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 1.35% of Vienna Insurance Group's portfolio in Q2 2026, its #18 holding.
Vienna Insurance Group first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 22 quarters since.
Vienna Insurance Group's Neurocrine Biosciences position peaked at $5.42M in Q4 2022.
778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Vienna Insurance Group's 13F filing for Q2 2026, filed 30 Jul 2026.